157 related articles for article (PubMed ID: 35408827)
1. Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy.
Passariello M; Yoshioka A; Takahashi K; Hashimoto SI; Rapuano Lembo R; Manna L; Nakamura K; De Lorenzo C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408827
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.
Manna L; Rapuano Lembo R; Yoshioka A; Nakamura K; Passariello M; De Lorenzo C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001604
[TBL] [Abstract][Full Text] [Related]
3. Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.
Passariello M; Yoshioka A; Takahashi K; Hashimoto SI; Inoue T; Nakamura K; De Lorenzo C
J Exp Clin Cancer Res; 2022 Sep; 41(1):269. PubMed ID: 36071464
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.
Vetrei C; Passariello M; Froechlich G; Rapuano Lembo R; Zambrano N; De Lorenzo C
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201082
[TBL] [Abstract][Full Text] [Related]
5. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.
Riccio G; Ricardo AR; Passariello M; Saraiva K; Rubino V; Cunnah P; Mertens N; De Lorenzo C
J Immunother; 2019 Jan; 42(1):1-10. PubMed ID: 30520849
[TBL] [Abstract][Full Text] [Related]
6. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
11. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.
Sasso E; D'Avino C; Passariello M; D'Alise AM; Siciliano D; Esposito ML; Froechlich G; Cortese R; Scarselli E; Zambrano N; Nicosia A; De Lorenzo C
MAbs; 2018 Oct; 10(7):1060-1072. PubMed ID: 29995563
[TBL] [Abstract][Full Text] [Related]
12. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Yuan Q; Liang Q; Sun Z; Yuan X; Hou W; Wang Y; Wang H; Yu M
Oncoimmunology; 2021; 10(1):1914954. PubMed ID: 34350059
[TBL] [Abstract][Full Text] [Related]
13. Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody.
Riccio G; Da Fonseca-Ricardo AR; Passariello M; Cunnah P; Mertens N; De Lorenzo C
J Immunother; 2017 May; 40(4):117-128. PubMed ID: 28125512
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
15. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
[TBL] [Abstract][Full Text] [Related]
16. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
17. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
20. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
